GemPharmatech announces research collaboration with leading cancer center to advance antibody discovery

GemPharmatech’s antibody discovery platform aims to accelerate development of next-generation cancer therapies

2025-10-22

(Press-News.org) SAN DIEGO, CALIF. — GemPharmatech, a global leader in preclinical research solutions and genetically-engineered mouse models, today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the discovery of new therapeutic antibodies.

Through the non-exclusive agreement, researchers at Memorial Sloan Kettering will have access to GemPharmatech’s extensive preclinical service capabilities and resources, utilizing the NeoMab® platform — a next-generation transgenic mouse model designed for rapid, efficient discovery of fully human therapeutic antibodies. The collaboration will help scientists at Memorial Sloan Kettering who are already tapping a wide range of leading-edge preclinical resources to further accelerate the development of fully human therapeutic antibodies against high-value targets and address urgent, unmet needs in cancer treatment.

“Our mission has always been to enable transformative biomedical research through innovative mouse models and technologies,” said Dr. Xiang Gao, founder of GemPharmatech. “Collaborating with MSK on antibody discovery represents a powerful opportunity to combine scientific excellence with cutting-edge mouse models such as NeoMab®. Together, we can accelerate the development of novel therapeutics that address some of the most urgent challenges in cancer treatment.”

Part of the world’s largest library of genetically engineered mouse models (GEMMs), the immunoglobulin gene-humanized mouse model- NeoMab®, carries the full variable gene repertoire of human heavy and kappa light chains, and regulatory elements, in a BALB/c background. This innovative design enables the rapid generation of diverse, high-affinity fully human antibodies without the need for time-consuming sequence humanization steps. By skipping this process, the collaboration aims to shorten antibody development timelines and reduce immunogenicity risks.

“This collaboration underscores our mission to provide the global research community with advanced platforms to accelerate innovations in drug discovery,” said Dr. Brandy Wilkinson, Chief Executive Officer of GemPharmatech. “We are excited to be supporting MSK’s pioneering work in oncology research with the NeoMab® platform. It is an honor to contribute to their scientific mission and to help advance antibody programs with the potential to transform therapies and improve patient outcomes worldwide.”

About GemPharmatech:

GemPharmatech is a leading global contract research organization offering end-to-end integrated preclinical services, built on the world’s largest library of genetically engineered mouse models and advanced in vivo platforms. With more than 25,000 strains of knockout, conditional knockout, humanized and immunodeficient mice, GemPharmatech enables researchers worldwide to accelerate therapeutic innovation across oncology, immunology, neurodegenerative diseases and beyond. The company also provides custom model generation and microbiome research services, along with custom breeding, vivarium rental services.

For more information, visit www.gempharmatech.com/.

END

ELSE PRESS RELEASES FROM THIS DATE:

Deciding whether a breathing tube is best for a child

2025-10-22

NEW YORK, NY – Oct. 22, 2025 – The emotional strain on parents and other caregivers faced with deciding whether a tracheotomy is the best treatment for their child is hard to measure. The latest clinical practice guideline from the American Thoracic Society aims to give clinicians and parents/caregivers a way forward so they can navigate difficult decisions to ensure better outcomes for young patients. The guideline was published early online today, Wednesday, Oct. 22, in the American Journal of Respiratory and Critical Care Medicine. A tracheostomy is a tube that is surgically placed through an ...

A ‘dead’ 1800s idea rises again... with clues to the mystery of the universe’s missing antimatter

2025-10-22

In 1867, Lord Kelvin imagined atoms as knots in the aether. The idea was soon disproven. Atoms turned out to be something else entirely. But his discarded vision may yet hold the key to why the universe exists. Now, for the first time, Japanese physicists have shown that knots can arise in a realistic particle physics framework, one that also tackles deep puzzles such as neutrino masses, dark matter, and the strong CP problem. Their findings, in Physical Review Letters, suggest these “cosmic knots” could have formed and briefly dominated in the turbulent newborn ...

Roboticists reverse engineer zebrafish navigation

2025-10-22

A paradox of neuroscience is that while brains evolve within specific sensory and physical environments, neural circuits are usually studied in isolation under controlled laboratory conditions. But we can’t fully understand how environmental factors shape brain function without considering the body in which that brain evolved. The BioRobotics Lab in EPFL’s School of Engineering specializes in developing bioinspired robots to tease apart the brain-body interactions involved in sensorimotor coordination. Now, they have published a study in Science Robotics that provides detailed insight into embodiment, or how the body ...

FAU historian traces the transformation of U.S. nursing homes into big business

2025-10-22

In postwar America, as suburbs spread and federal social welfare programs expanded, one underexamined building type quietly became a fixture of the American health care landscape: the nursing home. In a new article published in the Journal of the Society of Architectural Historians, historian Willa Granger, Ph.D., an assistant professor in the School of Architecture within Florida Atlantic University’s Dorothy F. Schmidt College of Arts and Letters, examines how a little-known company from midcentury Illinois helped lay ...

CABI study reveals major inequalities in global One Health research

2025-10-22

A study published in the journal CABI One Health has revealed major inequalities in One Health research. The new study, which sheds light on global trends in One Health research over the past decade, has found that the volume of research labelled ‘One Health’ has increased exponentially since 2018, and Europe, Asia and Africa have experienced the most marked growth in originating research. However, there are significant disparities in research decision-making between researchers in low- and middle-income countries (LMICs) and those in high-income countries ...

Reptiles ‘pee’ crystals, and scientists are investigating what they’re made of

2025-10-22

Unless you’ve owned reptiles, you might not know that many of them “pee” crystals. Researchers publishing in the Journal of the American Chemical Society investigated the solid urine of more than 20 reptile species and found spheres of uric acid in all of them. This work reveals how reptiles uniquely package up and eliminate crystalline waste, which could inform future treatments for human conditions that also involve uric acid crystals: kidney stones and gout. Most living things have some sort of excretory system — after all, what goes in must come out. In ...

Drug prevents congenital heart block recurrence in a high-risk pregnancy

2025-10-22

Congenital heart block, sometimes referred to as cardiac neonatal lupus, is a rare but potentially life-threatening condition that affects babies born to mothers with specific autoantibodies — called anti-SSA/Ro antibodies — which can attack the fetal heart via its electrical conduction system, leading to a slower heart rate. Most surviving infants with congenital heart block eventually require a pacemaker for life. In a study of one pregnant mother with systemic lupus erythematosus and high levels of anti-SSA/Ro antibodies, NYU Langone Health researchers found a drug that ...

Wiley announces winners of Advanced Science Young Innovator Award

2025-10-22

HOBOKEN, NJ—Eleven researchers have earned one of the most competitive early-career honors in interdisciplinary science: the 2025 Advanced Science Young Innovator Award. Wiley, a global leader in authoritative content and research intelligence and publisher of Advanced Science, announced the award recipients today. Selected from a highly competitive pool of 472 applicants across 40 countries, this year's winners represent the highest caliber of emerging scientists translating discoveries into real-world impact. Now in its second year, ...

Towards new ionic liquid-modified zeolite membranes for efficient CO2 conversion

2025-10-22

An effective strategy to address increasing greenhouse gas emissions and combat climate change is the capture and reuse of carbon dioxide (CO2). The reaction of CO2 and hydrogen (H2) can produce industrially useful chemicals, such as methanol and carbon monoxide, and synthetic fuels. However, in traditional reactors these chemical processes are limited by thermodynamic constraints and slow reaction rates, resulting in a low CO2 conversion. This is because these reactors reach equilibrium before all the reactants are converted into desired ...

UK Capital's ULEZ quickly cut air pollution —high vehicle compliance may have left little room for further gains after expansion

2025-10-22

People living, working and visiting London have seen substantial reductions in air pollution following the introduction of the Ultra Low Emissions Zone (ULEZ) introduced in 2019, according to a new research paper. In a study published in npj Clean Air today (Weds 22 October), researchers from the University of Birmingham have created a sophisticated model for assessing the direct impact of ULEZ on air pollution in the Greater London area. The team found that there were significant reductions in nitrogen-based pollutants NO2 and NOx following the introduction of ULEZ in 2019 that extended beyond the geographical boundaries of the zone, including areas that were covered ...

GemPharmatech announces research collaboration with leading cancer center to advance antibody discovery

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: